spacer
home > pmps > summer 2018 > connected health services and smart device solutions
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Connected Health Services and Smart Device Solutions

The market model for traditional pharmaceuticals, which is based on formulary positioning and prescriptions given by doctors, has been under pressure, giving rise to an end-user and consumer-driven approach. Additionally, changes in payment models have been linked to positive patient outcomes, otherwise known as ‘payment by results’.

For pharmaceuticals, the concept of patient centricity is a major trend, which – alongside more defined clinical/regulatory approaches, an increased number of biologic drugs, higher-drug specificity, and treatments linked to diagnostic data – is combining with a subsegmentation approach that concerns patients where drugs can be most effective. While efficacy and safety are still fundamental for gaining drug approval, also of importance is exploring and understanding the care journey provides valuable insight into the needs of stakeholders, as well as the basis for defining services that are essential for stakeholders and patients in subsegments. A service model that is dedicated to the drug will be able to meet individual and segment needs, including secondary disease measures, monitoring, and adherence and compliance services. Smooth interaction with stakeholders is critical for deriving value from this drug/ service differentiation. This change in the stakeholder/patient engagement equation evidences that bespoke connected health services are proving to be vital tools.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

Fujifilm Announces The Introduction Of A 10 Week Cell Line Development Timeline With Its Apollo™ X Advanced Mammalian Expression System

FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and gene therapies, has announced the reduction of cell line development timelines with its Apollo X™ Advanced Mammalian Expression System.
More info >>

White Papers
 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement